Tag - IMM

Developments

USPTO grants Immutep new patent for eftilagimod alfa combined with PD-1 pathway inhibitors

Immutep (ASX: IMM; NASDAQ: IMMP) has announced that the United States Patent and Trademark Office (USPTO) granted a new patent for eftilagimod alfa in combination with a PD-1 pathway inhibitor for the treatment of...

July 14, 2026

Developments

Immutep reports positive Phase 1 results for IMP761 in autoimmune diseases

Immutep (ASX: IMM; NASDAQ: IMMP) has announced positive Phase 1 results for IMP761, a first-in-class LAG-3 agonist antibody designed to potentially supress pathogenic T cell responses in autoimmune diseases. According...

March 19, 2026

Tag - IMM

USPTO grants Immutep new patent for eftilagimod alfa combined with PD-1 pathway inhibitors

Immutep reports positive Phase 1 results for IMP761 in autoimmune diseases

Subscribe